Protagonist Therapeutics - PTGX Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings or view top-rated stocks.

4 analysts have issued 1 year target prices for Protagonist Therapeutics' shares. Their PTGX share price forecasts range from $21.00 to $41.00. On average, they predict the company's stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 123.7% from the stock's current price.
View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts.

Protagonist Therapeutics' stock was trading at $10.91 at the beginning of 2023. Since then, PTGX shares have increased by 33.2% and is now trading at $14.53.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our PTGX earnings forecast.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.30. Protagonist Therapeutics had a negative trailing twelve-month return on equity of 46.74% and a negative net margin of 291.70%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Gratus Capital LLC (0.45%), Dupont Capital Management Corp (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), Allspring Global Investments Holdings LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel, Harold E Selick and Sarah B Noonberg.
View institutional ownership trends.

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PTGX stock can currently be purchased for approximately $14.53.

Protagonist Therapeutics (NASDAQ:PTGX) has a market capitalization of $714.88 million and generates $27.36 million in revenue each year. The company earns $-125,550,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.

The company employs 118 workers across the globe.

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The official website for the company is www.protagonist-inc.com. The company can be reached via phone at (510) 474-0170 or via email at bkorb@soleburytrout.com.